CLINICAL TRIALS PROFILE FOR SYMBICORT
✉ Email this page to a colleague
505(b)(2) Clinical Trials for SYMBICORT
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Dosage | NCT00812682 ↗ | Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler | Completed | AstraZeneca | 2006-09-01 | This study will evaluate the perception of the physicians and the patients about the approved adjustable dosing of Symbicort® 160/4,5. Symbicort maintenance dose will be adjusted up and down within the approved dose range of 1x2 - 4x2 inhalations per day, to the level of asthma symptoms. Patients and physicians perception of this new dosing schedule will be evaluated by means of questionnaires completion and direct questioning. | |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for SYMBICORT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00159263 ↗ | Effect of Symbicort on GR Localisation in Asthma | Completed | AstraZeneca | N/A | 2004-11-01 | To investigate a possible interaction between formoterol and budesonide on GR-translocation and to compare the effect of different doses of Symbicort (80/4.5 and 2x80/4.5 mcg) with the effect of budesonide (200 mcg and 800 mcg) on GR translocation, and to investigate the effect of the study drugs on exhaled NO (bronchial and alveolar fraction. |
| NCT00159263 ↗ | Effect of Symbicort on GR Localisation in Asthma | Completed | Imperial College London | N/A | 2004-11-01 | To investigate a possible interaction between formoterol and budesonide on GR-translocation and to compare the effect of different doses of Symbicort (80/4.5 and 2x80/4.5 mcg) with the effect of budesonide (200 mcg and 800 mcg) on GR translocation, and to investigate the effect of the study drugs on exhaled NO (bronchial and alveolar fraction. |
| NCT00206154 ↗ | A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients | Completed | AstraZeneca | Phase 3 | 2005-04-01 | The purpose of this study is to compare a combination asthma drug (Symbicort) with its two components, budesonide and formoterol, taken individually or in combination, and with placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) |
| NCT00206167 ↗ | A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD | Completed | AstraZeneca | Phase 3 | 2005-04-01 | The purpose of this study is to compare Symbicort in a pressurized metered-dose inhaler (pMDI) with formoterol and placebo in the long-term maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). |
| NCT00235911 ↗ | Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting | Completed | AstraZeneca | Phase 3 | 2003-09-01 | The primary objective is to compare the effects of Symbicort SiT and treatment according to NHG-guidelines on bronchial hyperresponsiveness in asthmatic patients, as measured by PD20 histamine, and to validate the Bronchial Hyperresponsiveness Questionnaire (BHQ). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for SYMBICORT
Condition Name
Clinical Trial Locations for SYMBICORT
Trials by Country
Clinical Trial Progress for SYMBICORT
Clinical Trial Phase
Clinical Trial Sponsors for SYMBICORT
Sponsor Name
